MX2019000660A - Compuestos, composiciones y métodos para el tratamiento de enfermedades. - Google Patents

Compuestos, composiciones y métodos para el tratamiento de enfermedades.

Info

Publication number
MX2019000660A
MX2019000660A MX2019000660A MX2019000660A MX2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A MX 2019000660 A MX2019000660 A MX 2019000660A
Authority
MX
Mexico
Prior art keywords
compositions
compounds
methods
disease
treatment
Prior art date
Application number
MX2019000660A
Other languages
English (en)
Inventor
P Iyer Radhakrishnan
Sheri Anjaneyulu
Padmanabhan Seetharamaiyer
Meher Geeta
Zhou Shenghua
Challa Sreerupa
Cleary Dillon
H Gimi Rayomand
Original Assignee
Sperovie Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sperovie Biosciences Inc filed Critical Sperovie Biosciences Inc
Publication of MX2019000660A publication Critical patent/MX2019000660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a compuestos y composiciones para la inducción de la expresión de un receptor de reconocimiento de patrones (por ejemplo, STING), y los métodos de uso de estos.
MX2019000660A 2016-07-15 2017-07-14 Compuestos, composiciones y métodos para el tratamiento de enfermedades. MX2019000660A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363123P 2016-07-15 2016-07-15
US201662411405P 2016-10-21 2016-10-21
PCT/US2017/042106 WO2018013908A1 (en) 2016-07-15 2017-07-14 Compounds, compositions, and methods for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2019000660A true MX2019000660A (es) 2019-10-02

Family

ID=60953343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000660A MX2019000660A (es) 2016-07-15 2017-07-14 Compuestos, composiciones y métodos para el tratamiento de enfermedades.

Country Status (13)

Country Link
US (1) US20190292215A1 (es)
EP (1) EP3484504A4 (es)
JP (1) JP2019521138A (es)
KR (1) KR20190039522A (es)
CN (1) CN109715202A (es)
AU (1) AU2017295883A1 (es)
CA (1) CA3030830A1 (es)
CR (1) CR20190071A (es)
IL (1) IL264156A (es)
MX (1) MX2019000660A (es)
PH (1) PH12019500095A1 (es)
SG (1) SG11201900154VA (es)
WO (1) WO2018013908A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006930A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
JP7195317B2 (ja) 2017-11-10 2022-12-23 武田薬品工業株式会社 Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3935066A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
KR20210137517A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
US20220259254A1 (en) 2019-07-05 2022-08-18 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
EP4192506A1 (en) 2020-08-07 2023-06-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CA3197167A1 (en) 2020-11-09 2022-05-12 He Xu Antibody drug conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
BR112012000828A8 (pt) * 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
JP2014500230A (ja) * 2010-08-30 2014-01-09 スプリング バンク ファーマシューティカルズ，インコーポレイテッド 治療薬としてオリゴヌクレオチド類縁体の設計
EP2956145A4 (en) * 2013-02-18 2016-08-17 Spring Bank Pharmaceuticals Inc DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINATE ADJUVANTIES AND THERAPEUTICS
ES2764178T3 (es) * 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
WO2017011622A1 (en) * 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors

Also Published As

Publication number Publication date
SG11201900154VA (en) 2019-02-27
JP2019521138A (ja) 2019-07-25
EP3484504A4 (en) 2020-07-29
WO2018013908A1 (en) 2018-01-18
AU2017295883A1 (en) 2019-02-21
CR20190071A (es) 2019-10-29
CA3030830A1 (en) 2018-01-18
US20190292215A1 (en) 2019-09-26
PH12019500095A1 (en) 2019-10-28
KR20190039522A (ko) 2019-04-12
IL264156A (en) 2019-02-28
CN109715202A (zh) 2019-05-03
EP3484504A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
PH12019500095A1 (en) Compounds, compositions, and methods for the treatment of disease
MX2022006260A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
MX2021010701A (es) Compuestos, composiciones y metodos para el tratamiento de enfermedad.
PH12015502788A1 (en) Antibody formulations and methods
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
GB2541571A (en) Pharmaceutical compositions
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2017003211A (es) Anticuerpos anti-met y composiciones.
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
NZ732208A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
EP3392348A3 (en) Method for selecting personalized tri-therapy for cancer treatment
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
DK3463351T3 (da) Behandling til parkinsons sygdom
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
EA201792527A1 (ru) Лечение зуда
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
PH12017501872A1 (en) Methods of treating diseases
PH12017501869A1 (en) (s)-2'-vinyl-abscisic acid derivatives
PH12019500038A1 (en) Compounds, compositions, and methods for the treatment of disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease